Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumor-associated antigen TA90 immune complex assay predicts recurrence andsurvival after surgical treatment of stage I-III melanoma
Autore:
Kelley, MC; Gupta, RK; Hsueh, EC; Yee, R; Stern, S; Morton, DL;
Indirizzi:
St Johns Hlth Ctr, John Wayne Canc Inst, Sonya Valley Ghidossi Vaccine Lab, Mt View, CA 94040 USA St Johns Hlth Ctr Mt View CA USA 94040 Vaccine Lab, Mt View, CA 94040 USA St Johns Hlth Ctr, John Wayne Canc Inst, Roy E Coats Res Labs, Mt View, CA94040 USA St Johns Hlth Ctr Mt View CA USA 94040 ats Res Labs, Mt View, CA94040 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 4, volume: 19, anno: 2001,
pagine: 1176 - 1182
SICI:
0732-183X(20010215)19:4<1176:TATICA>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT-MELANOMA; METASTATIC MELANOMA; PROGNOSTIC FACTORS; ADJUVANT THERAPY; PERIPHERAL-BLOOD; CELL VACCINE; IMMUNOTHERAPY; TOMOGRAPHY; MARKERS; MODEL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Morton, DL St Johns Hlth Ctr, John Wayne Canc Inst, Sonya Valley Ghidossi Vaccine Lab, 2200 Santa Monica Blvd, Mt View, CA 94040 USA St Johns Hlth Ctr 2200 Santa Monica Blvd Mt View CA USA 94040 A
Citazione:
M.C. Kelley et al., "Tumor-associated antigen TA90 immune complex assay predicts recurrence andsurvival after surgical treatment of stage I-III melanoma", J CL ONCOL, 19(4), 2001, pp. 1176-1182

Abstract

Purpose: Immune complexes (IC) containing the tumor-associated antigen TA90 can be identified in the sera of melanoma patients. We have shown that anenzyme-linked immunosorbent assay for TA90-IC can detect subclinical metastasis before surgical treatment of early-stage melanoma. We assayed the TA90-IC levels of postoperative sera from patients with melanoma and evaluatedtheir relationship to recurrence and survival. Patients and Methods: Multiple archival serum samples prospectively collected during postoperative surveillance of 166 patients with American Joint Committee on Cancer stage I, II, or III melanoma were analyzed for TA90-IC in a blinded fashion. Results were correlated with disease recurrence and survival determined by database and chart review. Results: TA90-IC status in the early postoperative period was strongly correlated with survival. Five-year overall survival rates were 84% far TA90-IC-negative patients and 36% for TA90-IC-positive patients (P = .0001). Respective 5-year disease-free survival rates were 74% and 24% (P = .0001). TheTA90-IC assay was a significant predictor of survival for both stage II and III patients. Multivariate analysis identified TA90-IC status as the strongest independent prognostic factor for both overall and disease-free survival. The TA90-IC essay wets elevated in 54 (77%) of 78 patients who developed recurrent disease, becoming positive 19 +/- 7 months before clinical evidence of recurrence. Overall, the assay detected recurrence with a sensitivity of 78% and specificity of 77%. Exclusion of patients receiving postoperative immunotherapy with a polyvalent melanoma cell vaccine increased sensitivity and specificity to 92% and 86%, respectively. Conclusion: The TA90-IC assay can accurately predict survival and detect the presence of subclinical disease after surgery for melanoma, which shouldbe useful in selecting patients for adjuvant therapy. Because the TA90-IC assay detected recurrence on an average of 19 months sooner than did routine clinical and radiographic evaluation, it may allow more timely therapeutic interventions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 21:40:27